Komori
KYORIN Pharmaceutical (4569) · InitiativeFirst stated

License Agreement with UBE for a Novel Drug Candidate

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Introduction of a novel therapeutic drug candidate compound license from UBEA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「In March 2026, we entered into a license agreement with Biodol for KRP-126 (BDT272), a drug candidate for neuropathic pain, and a license agreement with UBE Corporation for a novel drug candidate.」

    A license agreement for a novel drug candidate was signed with UBE Corporation in March 2026.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.